<DOC>
	<DOCNO>NCT00160706</DOCNO>
	<brief_summary>A follow-on safety study subject Crohn 's Disease previously withdraw double-blind study CDP870-031 [ NCT00152490 ] CDP870-032 [ NCT00152425 ] due exacerbation Crohn 's Disease .</brief_summary>
	<brief_title>A follow-on Safety Study Subjects With Crohn 's Disease Who Have Previously Been Withdrawn From Double-blind Study CDP870-031 NCT00152490 CDP870-032 NCT00152425 Due Exacerbation Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Participation either CDP870031 [ NCT00152490 ] CDP870032 [ NCT00152425 ] clinical study subject complete Week 2 assessment CDP870031 [ NCT00152490 ] Week 6 randomization CDP870032 [ NCT00152425 ] whose Crohn 's Disease significantly bad determined investigator whose Clinical Disease Activity Index ( CDAI ) score entry study either ( subject may receive active placebo treatment ) : 1 . At least 70 point high Baseline ( Week 0 CDP870031 [ NCT00152490 ] ; Week 6 CDP870 032 [ NCT00152425 ] responder ) OR 2 . Higher Baseline ( Week 0 CDP870031 [ NCT00152490 ] ; Week 6 CDP870032 [ NCT00152425 ] responder ) absolute score least 350 point Subjects must able understand information provide give write informed consent Any exclusion criterion would prevent subject 's participation qualify pivotal study ( CDP870031 [ NCT00152490 ] CDP870032 [ NCT00152425 ] ) , although upper limit 450 CDAI score applicable . In addition criterion exclude previous participation clinical trial Certolizumab Pegol apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>